Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region

Serological assays can detect anti-SARS-CoV-2 antibodies, but their sensitivity often comes at the expense of specificity. Here we developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against SARS-CoV-2. Calibration was performed with 90 prepandemic and 55 virologically and clinically confirmed COVID-19 samples. Posterior probabilities were calculated from 3×8 measurements of logarithmically diluted samples against the ectodomain and the receptor-binding domain of the spike protein and the nucleocapsid protein. We then performed 948’528 assays on 5’503 prepandemic and 34’019 copandemic samples from hospital patients and healthy blood donors. The seroprevalence increased in March 2020 (0.3%; CI95%: 0.1% - 0.5%) among hospital patients but plateaued in April at 1.1-1.3%, and dropped to 0.3-0.7% in July. A dynamic transmission model describing SARS-CoV-2 transmission and seroconversion in the general population of the Canton of Zurich yielded an infection fatality ratio of 0.6% (CI95%: 0.4%-0.8%), similarly to other European areas. While the evolution of seroprevalence points to a high effectiveness of containment measures, our data highlight that antibody waning warrants a continuous seromonitoring to reliably estimate the prevalence in a population.

[1]  C. Althaus,et al.  Time is of the essence: containment of the SARS-CoV-2 epidemic in Switzerland from February to May 2020 , 2020, medRxiv.

[2]  D. Altmann,et al.  SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection , 2020, Science Immunology.

[3]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[4]  E. MacMahon,et al.  Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection , 2020, medRxiv.

[5]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[6]  N. Low,et al.  Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe , 2020, PLoS medicine.

[7]  Ying Li,et al.  Antibody responses against SARS‐CoV‐2 in COVID‐19 patients , 2020, Journal of medical virology.

[8]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[9]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[10]  S. Lauer,et al.  Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland , 2020, medRxiv.

[11]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[12]  A. Aguzzi,et al.  Inflammatory olfactory neuropathy in two patients with COVID-19 , 2020, The Lancet.

[13]  Eric J Topol,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[14]  V. Torri,et al.  IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy, Italy , 2020, medRxiv.

[15]  M. Deijs,et al.  Human coronavirus reinfection dynamics: lessons for SARS-CoV-2 , 2020, medRxiv.

[16]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[17]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 , 2020, Antiviral Research.

[18]  L. Kucirka,et al.  Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.

[19]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[20]  A. Rinaldo,et al.  Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland. , 2020, Swiss medical weekly.

[21]  M. Nöthen,et al.  Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event , 2020 .

[22]  J. Lessler,et al.  Estimating the burden of SARS-CoV-2 in France , 2020, Science.

[23]  J. Ioannidis,et al.  COVID-19 antibody seroprevalence in Santa Clara County, California , 2020, medRxiv.

[24]  Kaijun Jiang,et al.  SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.

[25]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[26]  Mahan Ghafari,et al.  Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic , 2020, medRxiv.

[27]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[28]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[29]  Robin Krystufek,et al.  Increasing the throughput of crystallization condition screens: Challenges and pitfalls of acoustic dispensing systems , 2019, MethodsX.

[30]  Xinquan Wang,et al.  Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 , 2018, PLoS pathogens.

[31]  K. Wennerberg,et al.  Precision Cancer Medicine in the Acoustic Dispensing Era , 2016, SLAS technology.

[32]  C. Dobson,et al.  Microfluidic Diffusion Analysis of the Sizes and Interactions of Proteins under Native Solution Conditions. , 2016, ACS nano.

[33]  Weixian Lu,et al.  A time- and cost-efficient system for high-level protein production in mammalian cells. , 2006, Acta crystallographica. Section D, Biological crystallography.